Article · Wikipedia archive · Last revised Jul 27, 2026

25B-NB

25B-NB, also known as N-benzyl-4-bromo-2,5-dimethoxyphenethylamine, is a recreational designer drug from the 25-NB subgroup of the substituted phenethylamine family, with psychedelic effects. It has a binding affinity (Ki) of 16 nM at the serotonin receptor 5-HT2A and 90 nM at 5-HT2C and reportedly has a potency in between that of 2C-B and 25B-NBOMe (NBOMe-2C-B). 25B-NB was first synthesized and described by Richard Glennon and colleagues in 1994. It was the first drug of the 25-NB family to be developed. Subsequently, modification of 25B-NB led to the development of the more well-known 25-NB family drugs such as 25I-NBOMe. 25B-NB is a controlled substance in Canada under phenethylamine blanket-ban language.

Last revised
Jul 27, 2026
Read time
≈ 1 min
Length
289 w
Citations
10
Source
Wikipedia ↗
25B-NB
Clinical data
Other namesN-Benzyl-4-bromo-2,5-dimethoxyphenethylamine; N-Benzyl-2C-B; NB-2C-B
Drug classSerotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
  • In general Unscheduled
Identifiers
  • N-benzyl-2-(4-bromo-2,5-dimethoxyphenyl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H20BrNO2
Molar mass350.256 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCNCC2=CC=CC=C2)OC)Br
  • InChI=1S/C17H20BrNO2/c1-20-16-11-15(18)17(21-2)10-14(16)8-9-19-12-13-6-4-3-5-7-13/h3-7,10-11,19H,8-9,12H2,1-2H3
  • Key:XXLRSXIQVKHKPM-UHFFFAOYSA-N

25B-NB, also known as N-benzyl-4-bromo-2,5-dimethoxyphenethylamine (N-benzyl-2C-B or NB-2C-B), is a recreational designer drug from the 25-NB subgroup of the substituted phenethylamine family, with psychedelic effects. It has a binding affinity (Ki) of 16 nM at the serotonin receptor 5-HT2A and 90 nM at 5-HT2C and reportedly has a potency in between that of 2C-B and 25B-NBOMe (NBOMe-2C-B).12 25B-NB was first synthesized and described by Richard Glennon and colleagues in 1994.231 It was the first drug of the 25-NB family to be developed.23 Subsequently, modification of 25B-NB led to the development of the more well-known 25-NB family drugs such as 25I-NBOMe.23 25B-NB is a controlled substance in Canada under phenethylamine blanket-ban language.4

See also

See also

References

References

  1. Glennon RA, Dukat M, el-Bermawy M, Law H, De los Angeles J, Teitler M, King A, Herrick-Davis K (June 1994). "Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines". Journal of Medicinal Chemistry. 37 (13): 1929–1935. doi:10.1021/jm00039a004. PMID 8027974.
  2. Halberstadt AL (2017). "Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens". In Baumann M, Glennon R, Wiley J (eds.). Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. Cham: Springer. pp. 283–311. doi:10.1007/7854_2016_64. ISBN 978-3-319-52444-3. PMID 28097528.
  3. Poulie CB, Jensen AA, Halberstadt AL, Kristensen JL (December 2020). "DARK Classics in Chemical Neuroscience: NBOMes". ACS Chem Neurosci. 11 (23): 3860–3869. doi:10.1021/acschemneuro.9b00528. PMC 9191638. PMID 31657895.
  4. "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
External links